As Big Data analytics begin to inspire medical decisionmaking, companies and scientists have gone to war over access to data derived from patient biopsies. Cancer profiling is a seminal situation. While some companies are seeking to profit from approaches to advanced mutation analysis, researchers are vociferous in demanding open access to proprietary databases behind company firewalls.